Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

121.93 +2.18 (+1.82%)

Official Closing Price Updated: 7:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

27 28 Next >

MarketBeat Week in Review – 2/6 - 2/10

February 11, 2023

Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely

Via MarketBeat

Topics Artificial Intelligence Economy

Should Investors Buy or Sell the Vaccinex Patent News?

February 07, 2023

Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news?

Via MarketBeat

Topics Intellectual Property

Is Merck Stock a Buy After Its Post-Earnings Sell-Off?

February 07, 2023

Despite beating analysts’ expectations on the top and bottom lines, MRK stock fell after earnings. This article analyzes if investors should jump in

Via MarketBeat

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma

February 03, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results

February 02, 2023

From Merck & Co., Inc.

Via Business Wire

Cassava Sciences Stock Undervalued with Its $124 Price Target?

January 30, 2023

Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a

Via MarketBeat

FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)

January 27, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs

January 26, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility

January 25, 2023

From Merck & Co., Inc.

Via Business Wire

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial

January 25, 2023

From Merck & Co., Inc.

Via Business Wire

Is the Pain Over for Baudax Bio Investors after a 70% Spike?

January 25, 2023

Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.

Via MarketBeat

Merck Announces Second-Quarter 2023 Dividend

January 24, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.

January 11, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech

January 10, 2023

From Merck & Co., Inc.

Via Business Wire

Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2

January 05, 2023

From Merck & Co., Inc.

Via Business Wire

Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Merck & Co., Inc.

Via Business Wire

Big Health Care Stocks to Watch in the New Year

December 29, 2022

Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.

Via MarketBeat

Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

December 22, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer

December 22, 2022

From Merck & Co., Inc.

Via Business Wire

LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer

December 21, 2022

From Merck & Co., Inc.

Via Business Wire

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

December 20, 2022

From Seagen Inc.

Via Business Wire

AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer

December 15, 2022

From Merck & Co., Inc.

Via Business Wire

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

December 13, 2022

Via ACCESSWIRE

Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.

December 12, 2022

From Merck & Co., Inc.

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)

December 05, 2022

From Brodsky & Smith LLC

Via GlobeNewswire

Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting

December 01, 2022

From Merck & Co., Inc.

Via Business Wire

Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope

December 01, 2022

EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Intellectual Property

Merck Announces First-Quarter 2023 Dividend

November 29, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

November 22, 2022

From Merck & Co., Inc.

Via Business Wire

Imago BioSciences (NASDAQ: IMGO) to be Acquired by Merck (NYSE: MRK) for $1.35 Billion

November 21, 2022

Imago BioSciences, Inc. (NASDAQ: IMGO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development

Via Spotlight Growth

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

27 28 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Merck & Co (NY:MRK)

Press Releases about Merck & Co

Starting at $3.75/week.

Subscribe Today